AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMURON LTD

0.030

-0.002-6.25%

Volume:571.71K

Turnover:17.43K

Market Cap:9.80M

PE:-1.33

High:0.033

Open:0.033

Low:0.030

Close:0.032

52wk High:0.098

52wk Low:0.030

Shares:326.65M

Float Shares:265.37M

Volume Ratio:1.29

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.023

EPS(LYR):-0.023

ROE:-50.21%

ROA:-26.07%

PB:1.21

PE(LYR):-1.33

Loading ...

Overview Company News Filings

Concept

Pharmaceutical Companies-0.85%

Capital Flow

Inflow:

Outflow:

News

Immuron Limited Publishes Transcript of CEO Presentation at Emerging Growth Conference

Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target

BRIEF-Immuron Reports H1 Global Travelan Sales AUD$4.2 Mln

Immuron Limited Reports 5% Increase in Global H1 Sales

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMC.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","market":"AU","secType":"STK","nameCN":"IMMURON LTD","latestPrice":0.03,"timestamp":1770354720000,"preClose":0.032,"halted":0,"volume":571707,"delay":0,"changeRate":-0.06250000000000006,"nameEN":"IMMURON LTD","floatShares":265374293,"shares":326653609,"eps":-0.022586,"marketStatus":"Market Closed","change":-0.002,"latestTime":"02-06 16:12:00 AEDT","open":0.033,"high":0.033,"low":0.03,"amount":17427,"amplitude":0.09375,"askPrice":0.031,"askSize":168486,"bidPrice":0.03,"bidSize":148500,"shortable":3,"etf":0,"ttmEps":-0.022586,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770591600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.032,"openAndCloseTimeList":[[1770332400000,1770354000000]],"volumeRatio":1.2854373441717586,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","floatShares":265374293,"roa":"-26.07%","roe":"-50.21%","lyrEps":-0.022586,"volumeRatio":1.2854373441717586,"shares":326653609,"dividePrice":0,"high":0.033,"amplitude":0.09375,"preClose":0.032,"low":0.03,"week52Low":0.03,"pbRate":"1.21","psRate":"1.34","week52High":0.098,"institutionHeld":0,"latestPrice":0.03,"committee":-0.06305,"eps":-0.022586,"divideRate":0,"volume":571707,"delay":0,"ttmEps":-0.022586,"open":0.033,"prevYearClose":0.036,"prevWeekClose":0.035,"prevMonthClose":0.035,"prevQuarterClose":0.036,"fiveDayClose":0.035,"twentyDayClose":0.036,"sixtyDayClose":0.065},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-02-28","symbol":"IMC.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1677502800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMC.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMC.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606157291","title":"Immuron Limited Publishes Transcript of CEO Presentation at Emerging Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2606157291","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606157291?lang=en_us&edition=fundamental","pubTime":"2026-01-26 14:51","pubTimestamp":1769410282,"startTime":"0","endTime":"0","summary":"Immuron Limited has published the transcript of its CEO’s presentation at the Emerging Growth Conference, held virtually on January 22, 2026. The event featured Immuron’s Chief Executive Officer, Steven Lydeamore, who addressed investors and stakeholders about the company’s latest advancements. During the call, the CEO highlighted Immuron’s proprietary technology, which utilizes polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum to target infectious diseases. “Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by digestive enzymes,” stated the CEO, emphasizing the unique benefits of the company’s orally active antibody therapies. Key developments discussed included the progress of IMM-124E , designed to combat enterotoxigenic Escherichia coli , and ongoing collaborations with Monash University to develop IMM-529 for targeting Clostridioides difficile. The CEO noted, “This unique 3-target approach has yielded prom","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL9Htw1Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2605460193","title":"Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2605460193","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605460193?lang=en_us&edition=fundamental","pubTime":"2026-01-22 19:00","pubTimestamp":1769079651,"startTime":"0","endTime":"0","summary":"Emerging Growth Research has released a Flash Research Update on Immuron Limited , maintaining its Buy-Extended rating and setting a 12-month price target of $3.50. The report highlights Immuron’s first-half fiscal 2026 results, noting global revenue of AUD$4.2 million—a 5% increase from the previous year—driven by continued demand for its Travelan immune supplement in Australia and the U.S. The analysis points to Immuron’s combination of commercial revenue, early traction in key markets, and clinical development pipeline as key strengths, while acknowledging ongoing reliance on external capital for clinical progress. The $3.50 price target is based on a peer-group EV/Revenue valuation, adjusted for the company’s ADS structure.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL2t9Qry:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2604139014","title":"BRIEF-Immuron Reports H1 Global Travelan Sales AUD$4.2 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2604139014","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604139014?lang=en_us&edition=fundamental","pubTime":"2026-01-19 22:25","pubTimestamp":1768832724,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Reports H1 Global Travelan Sales AUD$4.2 MlnJan 19 (Reuters) - Immuron Ltd IMC.AX:IMMURON REPORTS CONTINUED SALES GROWTHIMMURON LTD - H1 GLOBAL      TRAVELAN SALES AUD$4.2 MILLIONSource text: ID:nGNX6r0VRNFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nTUA8NBSQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2604801571","title":"Immuron Limited Reports 5% Increase in Global H1 Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2604801571","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604801571?lang=en_us&edition=fundamental","pubTime":"2026-01-19 19:00","pubTimestamp":1768820419,"startTime":"0","endTime":"0","summary":"Immuron Limited has reported continued sales growth for the first half  of the fiscal year. Global H1 sales reached AUD$4.2 million, an increase of 5% compared to the prior comparative period . Second quarter  global sales were AUD$2.2 million, up 11% on the previous quarter. In Australia, H1 sales totaled AUD$3.3 million, up 13% on pcp, with Q2 sales of AUD$1.7 million, an 11% increase on the prior quarter. The company also launched ProIBS in Australia during this period. In the USA, H1 sales were AUD$0.9 million, representing a 17% increase on pcp, with Q2 sales of AUD$0.4 million, up 8% from the previous quarter. Canadian H1 sales were AUD$56 thousand, down 85% on pcp, but Q2 sales rose to AUD$42 thousand, an increase of 191% on the prior quarter. Immuron anticipates further growth in Canada with the upcoming launch of Travelan in Jean Coutu pharmacies in Quebec.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDL6pKhxb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","SG9999014005.SGD","BK4585","LU2210149790.SGD","SG9999014021.USD","IMC.AU","BK4112","BK4588","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK7508","IE00B64PRP62.GBP","SG9999014039.USD","LU2095319765.USD","BK7067","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014013.SGD"],"gpt_icon":0}],"pageSize":4,"totalPage":15,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IMC.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"Pharmaceutical Companies","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.008451}]}}